1. B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. (5th April 2022) Authors: Mateos, M; Hari, P; Bahlis, N; Chari, A; van de Donk, NWCJ; Dholaria, B; Garfall, AL; Goldschmidt, H; Kortüm, KM; Krishnan, A; Martin, T; Morillo, D; Oriol, A; Reece, D; Rodriguez, C; Rodríguez-Otero, P; San-Miguel, JF; Usmani, SZ; Verona, R; Lin, SXW Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗